Q1 FY27 results: revenue up 53% YoY; acquires related-party plant for Rs 29.98 cr

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.0%Reaction day

₹147.00

prior close

₹154.35

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%+4.6% vs market

Specialty Chemicals peers, median of 94sector-0.1%+5.1% vs sector

On the reaction day the stock moved 4.6 pts more than Nifty Microcap 250 and 5.1 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.0+0.4+4.6-0.1+5.1

Next day

+10.2+1.7+8.5+0.4+9.8

+15.7+2.1+13.7+0.8+14.9

+16.2+2.1+14.1+0.9+15.3

+21.2+2.1+19.1+0.9+20.3

+24.5+1.9+22.6+0.7+23.7

+19.7+2.4+17.3+1.5+18.2

15d

+13.3+3.0+10.2+1.4+11.9

+9.9+3.7+6.2+3.4+6.5

+29.3+1.6+27.7+0.4+28.9

—————

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 94Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Resonance Specialties posted Q1 FY27 revenue of Rs 32.58 cr, up 53% YoY from Rs 21.27 cr. Net profit surged to Rs 5.74 cr from Rs 1.63 cr YoY, with EPS at Rs 4.98 vs Rs 1.41. Separately, the board approved buying a Mandideep (Madhya Pradesh) manufacturing unit from Kaygee Laboratories (promoter group firm) for Rs 29.98 cr on slump sale basis. The WHO-approved facility makes chemical intermediates and APIs for the company and is subject to shareholder approval.

Likely market impact

Strong YoY growth boosts earnings; acquisition brings in-house a key plant supplying the company, subject to shareholder nod.